Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Johnson

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
End points and United States Food and Drug Administration approval of oncology drugsJohn R Johnson, Grant Williams, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiformeMartin H Cohen, John R Johnson, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approvalMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|July 1, 2008
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphomaMartin H Cohen, John R Johnson, Robert Justice, et al.
The Oncologist|October 13, 2004
FDA drug approval summaries: pemetrexed (Alimta)Maitreyee Hazarika, Robert M White, John R Johnson, et al.
The Oncologist|May 31, 2012
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumorsMartin H Cohen, John R Johnson, Robert Justice, et al.
Journal of Neurosurgery. Spine|June 4, 2016
Posterior reversible encephalopathy syndrome following a thoracic discectomy-induced dural leak: case reportLisa B E Shields, John R Johnson, Christopher B Shields
The Oncologist|November 18, 2011
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approvalMartin H Cohen, John R Johnson, Robert Justice, et al.
Orthopedics|October 29, 2002
Surgical management of adjacent level degeneration following lumbar spine fusionSteven D Glassman, Kevin Pugh, John R Johnson, et al.
Spine|July 20, 2002
Vertebral osteonecrosis associated with the use of intradiscal electrothermal therapy: a case reportMladen Djurasovic, Steven D Glassman, John R Dimar, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
End points and United States Food and Drug Administration approval of oncology drugsJohn R Johnson, Grant Williams, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiformeMartin H Cohen, John R Johnson, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approvalMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|July 1, 2008
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphomaMartin H Cohen, John R Johnson, Robert Justice, et al.
The Oncologist|October 13, 2004
FDA drug approval summaries: pemetrexed (Alimta)Maitreyee Hazarika, Robert M White, John R Johnson, et al.
The Oncologist|May 31, 2012
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumorsMartin H Cohen, John R Johnson, Robert Justice, et al.
Journal of Neurosurgery. Spine|June 4, 2016
Posterior reversible encephalopathy syndrome following a thoracic discectomy-induced dural leak: case reportLisa B E Shields, John R Johnson, Christopher B Shields
The Oncologist|November 18, 2011
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approvalMartin H Cohen, John R Johnson, Robert Justice, et al.
Orthopedics|October 29, 2002
Surgical management of adjacent level degeneration following lumbar spine fusionSteven D Glassman, Kevin Pugh, John R Johnson, et al.
Spine|July 20, 2002
Vertebral osteonecrosis associated with the use of intradiscal electrothermal therapy: a case reportMladen Djurasovic, Steven D Glassman, John R Dimar, et al.
Pageof 6